A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

BACKGROUND: Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against the current dosing strategies. The primary objectives were to determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurkmans, Daan P., Basak, Edwin A., van Dijk, Tanja, Mercieca, Darlene, Schreurs, Marco W. J., Wijkhuijs, Annemarie J. M., Bins, Sander, Hoop, Esther Oomen-de, Debets, Reno, Joerger, Markus, Odink, Arlette, van der Veldt, Astrid A. M., van der Leest, Cor H., Aerts, Joachim G. J. V., Mathijssen, Ron H. J., Koolen, Stijn L. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642527/
https://www.ncbi.nlm.nih.gov/pubmed/31324223
http://dx.doi.org/10.1186/s40425-019-0669-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642527/
https://www.ncbi.nlm.nih.gov/pubmed/31324223
http://dx.doi.org/10.1186/s40425-019-0669-y

Ejemplares similares